Opportunity Information: Apply for PAR 22 185
The Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program (X01 Clinical Trial Not Allowed) is a National Institutes of Health (NIH) funding opportunity designed to help researchers move promising HIV therapeutics closer to the clinic by providing access to targeted, "gap-filling" preclinical services. Rather than primarily serving as a traditional research grant to fund an entire project from start to finish, this program is structured as a way for investigators to request specific preclinical development support that they may not have in-house, may be too expensive to obtain independently, or may be a bottleneck preventing further advancement of a candidate therapy. The overall aim is to speed the development pipeline for new therapeutics addressing HIV and key HIV-associated co-infections, specifically Hepatitis B, Hepatitis C, and Tuberculosis.
A central feature of this opportunity is its emphasis on practical product-development needs in the preclinical stage. The program is geared toward helping academic groups and private sector teams overcome missing pieces that stand between a promising concept or lead compound and the next stage of development. In plain terms, it supports the kind of enabling work that often determines whether a therapeutic candidate can credibly progress toward human testing, such as specialized studies, assays, or other preclinical services intended to strengthen a development package. Even though the award mechanism is listed as a grant, the FOA language highlights services-oriented support to facilitate product advancement, and it explicitly states that clinical trials are not allowed under this opportunity.
The opportunity is listed as discretionary funding and uses a grant funding instrument, with a health-related activity category and CFDA number 93.855. The Funding Opportunity Number is PAR 22 185, and it was created on May 27, 2022. The original closing date provided is January 17, 2025. The notice does not specify an award ceiling or the expected number of awards in the provided source data, which usually means applicants should rely on the full FOA text and any related NIH guide notices for details on scope, available resources, review considerations, and any limits tied to the particular services requested.
Eligibility is broad and inclusive, reflecting the program's intent to support a wide range of institutions and organizations involved in HIV and co-infection therapeutic development. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; and Native American tribal organizations other than federally recognized tribal governments. Nonprofit organizations are eligible whether or not they hold 501(c)(3) status, and both for-profit organizations (other than small businesses) and small businesses may apply. Public housing authorities/Indian housing authorities are also included, along with an "others" category that is further expanded by the FOA to explicitly name additional eligible groups.
The FOA also calls out several categories of institutions and organizations as eligible, underscoring an effort to broaden participation and ensure access across diverse communities and regions. These include Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); faith-based or community-based organizations; eligible federal agencies; regional organizations; U.S. territories or possessions; and even non-domestic (non-U.S.) entities, meaning foreign organizations may apply. It also notes eligibility for Indian/Native American tribal governments other than federally recognized ones, which can be important for certain community-based or tribally affiliated research and development efforts.
Taken together, RAPIDD is best understood as an NIH pathway for researchers who already have a therapeutic concept or candidate with promise in HIV or HIV-related co-infections, but who need specific preclinical development help to de-risk the candidate and build a stronger case for the next stages of translation. The program targets the kinds of preclinical gaps that can stall progress and offers a structured way to obtain the services needed to push viable therapeutics forward, while keeping the work firmly on the preclinical side (no clinical trials).Apply for PAR 22 185
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program (X01 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855.
- This funding opportunity was created on 2022-05-27.
- Applicants must submit their applications by 2025-01-17. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the RAPIDD Program?
The Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program is a National Institutes of Health (NIH) funding opportunity that helps researchers advance promising HIV therapeutics toward the clinic by providing access to targeted preclinical development services. It is described as “gap-filling” support intended to overcome specific bottlenecks in the preclinical pipeline.
What is the official funding opportunity name and identifier?
The opportunity is titled “Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program (X01 Clinical Trial Not Allowed).” The Funding Opportunity Number is PAR 22 185.
What is the main purpose of this opportunity?
The main purpose is to speed the development pipeline for new therapeutics that address HIV and key HIV-associated co-infections by providing access to practical, product-development-focused preclinical services that strengthen a development package and help a candidate credibly progress toward human testing.
Is this a traditional research grant that funds an entire project end-to-end?
No. While the instrument is listed as a grant, the description emphasizes a services-oriented model. The program is positioned as a way to request specific preclinical development support (targeted services) rather than funding an entire research project from start to finish.
What kinds of support does RAPIDD provide?
RAPIDD is focused on “gap-filling” preclinical services that investigators may not have in-house, may be too expensive to obtain independently, or that represent a development bottleneck. The description highlights enabling preclinical work such as specialized studies, assays, or other services intended to strengthen the overall preclinical development package.
What stage of development is RAPIDD intended to support?
It is intended for the preclinical stage, particularly when a therapeutic concept or lead candidate shows promise but needs additional preclinical development work to reduce risk and support advancement to the next stage of translation.
Are clinical trials allowed under this opportunity?
No. The opportunity explicitly states “Clinical Trial Not Allowed,” and it emphasizes keeping supported work firmly on the preclinical side.
What disease areas are in scope?
The program targets therapeutics addressing HIV and key HIV-associated co-infections, specifically Hepatitis B, Hepatitis C, and Tuberculosis.
Who is the funding agency?
The funding agency is the National Institutes of Health (NIH).
What is the funding instrument and category?
The opportunity is listed as discretionary funding and uses a grant funding instrument. It is categorized as a health-related activity.
What is the CFDA number for this opportunity?
The CFDA number listed is 93.855.
When was this funding opportunity created?
The opportunity was created on May 27, 2022.
What is the closing date?
The original closing date provided is January 17, 2025.
Does the provided information state an award ceiling or the expected number of awards?
No. The provided source data does not specify an award ceiling or the expected number of awards. Applicants are directed (by implication) to rely on the full FOA text and related NIH notices for details such as scope, available resources, review considerations, and any limits tied to requested services.
Who is eligible to apply?
Eligibility is broad. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; and Native American tribal organizations other than federally recognized tribal governments.
Are nonprofit organizations eligible?
Yes. Nonprofit organizations are eligible whether or not they have 501(c)(3) status.
Are for-profit organizations eligible?
Yes. For-profit organizations (other than small businesses) are eligible, and small businesses may also apply.
Are public housing authorities eligible?
Yes. Public housing authorities/Indian housing authorities are included among eligible applicants.
Are U.S. territories or possessions eligible?
Yes. The FOA explicitly includes U.S. territories or possessions among eligible groups.
Are foreign (non-U.S.) organizations eligible to apply?
Yes. The FOA notes that non-domestic (non-U.S.) entities are eligible, meaning foreign organizations may apply.
Are tribal entities beyond federally recognized tribal governments included?
Yes. Eligibility includes Indian/Native American tribal governments other than federally recognized ones and Native American tribal organizations other than federally recognized tribal governments.
Are certain institution types explicitly encouraged or called out as eligible?
Yes. The FOA calls out a number of institution categories as eligible, including Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); and faith-based or community-based organizations.
Are federal agencies eligible applicants?
Yes. The FOA explicitly lists eligible federal agencies among eligible groups.
Are regional organizations eligible?
Yes. Regional organizations are included among the explicitly named eligible groups.
What is the overall rationale for the program’s “gap-filling” approach?
The program is designed to address missing preclinical development pieces that can prevent a promising candidate therapy from progressing. It aims to provide access to specialized services that help de-risk and strengthen the preclinical package so the therapeutic has a clearer path toward the next stages of development.
If my team already has strong in-house preclinical capabilities, is RAPIDD still relevant?
The description frames RAPIDD as particularly useful when needed preclinical services are not available in-house, are too expensive to obtain independently, or represent a bottleneck. Based on the provided information, the best fit is when a specific preclinical gap is preventing further advancement.
Where should applicants look for details not included in the summary (like limits tied to requested services)?
The summary indicates that key details such as scope, available resources, review considerations, and any service-specific limits may be found in the full FOA text and any related NIH Guide notices.
Browse more opportunities from the same category: Health
Next opportunity: Cooperative Agreement for CESU-affiliated Partner with Rocky Mountain Cooperative Ecosystem Studies Unit
Previous opportunity: NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 22 185
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 22 185) also looked into and applied for these:
| Funding Opportunity |
|---|
| NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed) Apply for PAR 22 194 Funding Number: PAR 22 194 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Data Management Coordinating Center for Diagnostic Centers of Excellence (U2C Clinical Trial Not Allowed) Apply for RFA NS 22 051 Funding Number: RFA NS 22 051 Agency: National Institutes of Health Category: Health Funding Amount: $3,000,000 |
| Measures and Methods for Research on Family Caregivers for People Living with Alzheimers Disease and Related Dementias (AD/ADRD) (R21 Clinical Trial Not Allowed) Apply for RFA AG 23 023 Funding Number: RFA AG 23 023 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Measures and Methods for Research on Family Caregivers for People Living with Alzheimers Disease and Related Dementias (AD/ADRD) (R01 Clinical Trial Not Allowed) Apply for RFA AG 23 022 Funding Number: RFA AG 23 022 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pragmatic Clinical Trials in Community Settings to Decrease or Prevent VCID Outcomes, Including in Populations that Experience Health Disparities (U01 Clinical Trial Required) Apply for RFA NS 23 001 Funding Number: RFA NS 23 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional) Apply for PAS 22 196 Funding Number: PAS 22 196 Agency: National Institutes of Health Category: Health Funding Amount: $1,838,436 |
| Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional) Apply for PAS 22 197 Funding Number: PAS 22 197 Agency: National Institutes of Health Category: Health Funding Amount: $1,838,436 |
| Transformative Artificial Intelligence and Machine Learning Based Strategies to Identify Determinants of Exceptional Health and Life Span (R21/R33 Clinical Trial Not Allowed) Apply for RFA AG 23 033 Funding Number: RFA AG 23 033 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Structural Biology of Alzheimer's Disease Related Dementias (ADRDs) Proteinopathies (R01 Clinical Trial Not Allowed) Apply for PAR 22 208 Funding Number: PAR 22 208 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Molecular Dynamics of HIV (R01 Clinical Trial Not Allowed) Apply for RFA AI 22 050 Funding Number: RFA AI 22 050 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed) Apply for RFA TR 22 030 Funding Number: RFA TR 22 030 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Harnessing Technologies to Support Oral Health Promotion and Management Outside the Dental Setting (UG3/UH3 Clinical Trial Required) Apply for RFA DE 23 009 Funding Number: RFA DE 23 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Claude D. Pepper Older Americans Independence Centers (P30 Clinical Trial Optional) Apply for RFA AG 23 017 Funding Number: RFA AG 23 017 Agency: National Institutes of Health Category: Health Funding Amount: $925,000 |
| Impact of the Microbiome-Gut-Brain Axis on Alzheimer's Disease and Alzheimer's Disease-Related Dementias (R01 Clinical Trial Not Allowed) Apply for PAR 22 211 Funding Number: PAR 22 211 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R43/R44 Clinical Trial Optional) Apply for RFA AG 23 029 Funding Number: RFA AG 23 029 Agency: National Institutes of Health Category: Health Funding Amount: $1,838,436 |
| Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed) Apply for PAR 22 170 Funding Number: PAR 22 170 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R41/R42 Clinical Trial Optional) Apply for RFA AG 23 030 Funding Number: RFA AG 23 030 Agency: National Institutes of Health Category: Health Funding Amount: $1,838,436 |
| New Epidemiological Cohort Study among Asian Americans, Native Hawaiians, and Pacific Islanders (AsA-NHPI): Clinical/Community Field Centers (UG3/UH3 - Clinical Trial Not Allowed) Apply for RFA HL 23 015 Funding Number: RFA HL 23 015 Agency: National Institutes of Health Category: Health Funding Amount: $373,000 |
| Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional) Apply for PAR 22 213 Funding Number: PAR 22 213 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| New Epidemiological Cohort Study among Asian Americans, Native Hawaiians, and Pacific Islanders (AsA-NHPI): Coordinating Center (U24 - Clinical Trial Not Allowed) Apply for RFA HL 23 016 Funding Number: RFA HL 23 016 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 22 185", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.